AVEO Pharmaceuticals Inc
NASDAQ:AVEO
Other Pre-Announcement
Aveo Oncology Reports First Quarter 2022 Financial Results
Published: 05/05/2022 11:32 GMT
AVEO Pharmaceuticals Inc (AVEO) - Aveo Oncology Reports First Quarter 2022 Financial Results.
Aveo Oncology - Total Q1 2022 Net Revenue of $20.9 Million.
Aveo Oncology - Company Reaffirms Full Year 2022 Fotivda U.S. Net Product Revenue Guidance of $100 to $110 Million.
Aveo Oncology - Net Loss for Q1 of 2022 Was $10.2 Million, Or Net Loss of $0.30 per Basic and Diluted Share.
Q1 Earnings per Share View $-0.25, Revenue View $20.7 Million -- Refinitiv Ibes Data (analyst estimates).
Aveo Oncology - Total Q1 2022 Net Revenue of $20.9 Million.
Aveo Oncology - Company Reaffirms Full Year 2022 Fotivda U.S. Net Product Revenue Guidance of $100 to $110 Million.
Aveo Oncology - Net Loss for Q1 of 2022 Was $10.2 Million, Or Net Loss of $0.30 per Basic and Diluted Share.
Q1 Earnings per Share View $-0.25, Revenue View $20.7 Million -- Refinitiv Ibes Data (analyst estimates).